Literature DB >> 27001823

Oritavancin Activity Tested against Molecularly Characterized Staphylococci and Enterococci Displaying Elevated Linezolid MIC Results.

Rodrigo E Mendes1, David J Farrell2, Helio S Sader2, Robert K Flamm2, Ronald N Jones2.   

Abstract

Oritavancin (MIC50/90, 0.03/0.06 to 0.12 μg/ml) had potent activity against linezolid-resistant staphylococci, as well as Enterococcus faecalis and Enterococcus faecium (oritavancin MIC50/90, 0.015/0.12 μg/ml against both species). All linezolid-resistant isolates were inhibited by oritavancin at ≤0.12 μg/ml. These results confirmed the absence of cross-resistance between linezolid and oritavancin in staphylococci and enterococci.
Copyright © 2016, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27001823      PMCID： PMC4879412          DOI： 10.1128/AAC.00281-16

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  24 in total

1.  Update on linezolid in vitro activity through the Zyvox Annual Appraisal of Potency and Spectrum Program, 2013.

Authors:  Rodrigo E Mendes; Patricia A Hogan; Jennifer M Streit; Ronald N Jones; Robert K Flamm
Journal:  Antimicrob Agents Chemother       Date:  2015-02-02       Impact factor: 5.191

2.  National prevalence of methicillin-resistant Staphylococcus aureus in inpatients at United States health care facilities, 2010.

Authors:  William R Jarvis; Ashley A Jarvis; Raymond Y Chinn
Journal:  Am J Infect Control       Date:  2012-04       Impact factor: 2.918

3.  In vitro activity of linezolid as assessed through the 2013 LEADER surveillance program.

Authors:  Robert K Flamm; Rodrigo E Mendes; Patricia A Hogan; James E Ross; David J Farrell; Ronald N Jones
Journal:  Diagn Microbiol Infect Dis       Date:  2014-12-30       Impact factor: 2.803

4.  When is coagulase-negative Staphylococcus bacteraemia clinically significant?

Authors:  Elisa García-Vázquez; Ana Fernández-Rufete; Alicia Hernández-Torres; Manuel Canteras; Joaquín Ruiz; Joaquín Gómez
Journal:  Scand J Infect Dis       Date:  2013-07-01

5.  Oritavancin: mechanism of action.

Authors:  George G Zhanel; Frank Schweizer; James A Karlowsky
Journal:  Clin Infect Dis       Date:  2012-04       Impact factor: 9.079

6.  Nosocomial outbreak of methicillin- and linezolid-resistant Staphylococcus epidermidis associated with catheter-related infections in intensive care unit patients.

Authors:  Cristina Seral; Yolanda Sáenz; Sonia Algarate; Estrella Duran; Pilar Luque; Carmen Torres; Francisco Javier Castillo
Journal:  Int J Med Microbiol       Date:  2011-01-14       Impact factor: 3.473

7.  Wide dissemination of linezolid-resistant Staphylococcus epidermidis in Greece is associated with a linezolid-dependent ST22 clone.

Authors:  Vasilios Karavasilis; Olympia Zarkotou; Maria Panopoulou; Melina Kachrimanidou; Katerina Themeli-Digalaki; Antonios Stylianakis; Vassiliki Gennimata; Eleni Ntokou; Constantinos Stathopoulos; Athanasios Tsakris; Spyros Pournaras
Journal:  J Antimicrob Chemother       Date:  2015-02-23       Impact factor: 5.790

8.  The site of action of oxazolidinone antibiotics in living bacteria and in human mitochondria.

Authors:  Karen L Leach; Steven M Swaney; Jerry R Colca; William G McDonald; James R Blinn; Lisa M Thomasco; Robert C Gadwood; Dean Shinabarger; Liqun Xiong; Alexander S Mankin
Journal:  Mol Cell       Date:  2007-05-11       Impact factor: 17.970

9.  Detection of a New cfr-Like Gene, cfr(B), in Enterococcus faecium Isolates Recovered from Human Specimens in the United States as Part of the SENTRY Antimicrobial Surveillance Program.

Authors:  Lalitagauri M Deshpande; Deborah S Ashcraft; Heather P Kahn; George Pankey; Ronald N Jones; David J Farrell; Rodrigo E Mendes
Journal:  Antimicrob Agents Chemother       Date:  2015-07-27       Impact factor: 5.191

10.  Linezolid dependence in Staphylococcus epidermidis bloodstream isolates.

Authors:  Spyros Pournaras; Eleni Ntokou; Olympia Zarkotou; Kyriaki Ranellou; Katerina Themeli-Digalaki; Constantinos Stathopoulos; Athanassios Tsakris
Journal:  Emerg Infect Dis       Date:  2013-01       Impact factor: 6.883
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.